Arthneeti

Novelix Pharmaceuticals Share Price & Earnings Call Analysis

₹64.20-2.74% today
Market cap
₹183 Cr
P/E
50.50
ROE
8.00%
PEG
0.19
Price to sales
1.24
Debt to equity
0.00
52W high / low
₹88.8 / ₹50.3
Sales growth (5Y)
151.69%
EBITDA margin
3.13%
Net profit margin
1.93%
Promoter holding
54.29%
Sales (last year)
₹147 Cr

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Novelix Pharmaceuticals rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Financials of Novelix Pharmaceuticals

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Novelix Pharmaceuticals

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +0.430.871.950.930.500.840.603.965.3020.8622.3536.3648.40
Expenses +0.521.072.141.040.610.691.043.745.1720.6322.1735.6647.09
Operating Profit-0.09-0.20-0.19-0.11-0.110.15-0.440.220.130.230.180.701.31
OPM %-20.93%-22.99%-9.74%-11.83%-22.00%17.86%-73.33%5.56%2.45%1.10%0.81%1.93%2.71%
Other Income +0.180.230.050.050.090.130.10-0.080.000.000.000.030.00
Interest0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation0.020.010.010.010.010.010.000.000.000.020.010.010.03
Profit before tax0.070.02-0.15-0.07-0.030.27-0.340.140.130.210.170.721.28
Tax %0.00%0.00%6.67%0.00%0.00%0.00%2.94%0.00%-15.38%14.29%41.18%26.39%21.88%
Net Profit +0.070.01-0.17-0.07-0.030.28-0.350.130.150.180.110.531.00
EPS in Rs0.090.01-0.21-0.09-0.040.35-0.350.130.150.180.090.370.58

Financials of Novelix Pharmaceuticals

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +6114342112431128
Expenses +5113331432431126
Operating Profit1000000-3-20-002
OPM %16%33%43%5%15%6%12%-244%-151%0%-6%0%2%
Other Income +0000-000000000
Interest0000000000000
Depreciation0000000000000
Profit before tax1000000-3-2-0002
Tax %32%88%31%24%34%-32%20%0%-1%0%50%33%
Net Profit +0000000-3-2-0002
EPS in Rs0.520.020.120.190.220.310.11-4.04-1.93-0.070.010.081.22
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Novelix Pharmaceuticals

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital888888888881014
Reserves33334441-1-1-1811
Borrowings +0000000000000
Other Liabilities +000000000001046
Total Liabilities1212121212121297772772
Fixed Assets +1111100020001
CWIP0000000000000
Investments0132334413300
Other Assets +1098999855442771
Total Assets1212121212121297772772

Financials of Novelix Pharmaceuticals

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +0-02-11-0111-2-0-14
Cash from Investing Activity +0-0-21-10-000003
Cash from Financing Activity +-0-000000000011
Net Cash Flow0-10-0-00111-2-01
Free Cash Flow-0-12-11-010-1-2-0-14
CFO/OP3%-90%472%-535%225%-220%672%-18%-34%136%-9,771%

Financials of Novelix Pharmaceuticals

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days5430440130216192532361216
Inventory Days280281913398923922211310
Days Payable405413540140115
Cash Conversion Cycle77304689521654111271244114111
Working Capital Days5712,2252,5848639328581,711819647743346197
ROCE %5%1%1%1%3%1%1%-31%-19%-1%0%1%